BPC-157 is a 15-amino-acid peptide, a fragment of a protein found in gastric juice. It is one of the most searched peptides online, and its marketing describes healing of tendons, muscles, the gut and nerves. Those claims rest mostly on animal studies. This article separates what has been seen in animals from what has been seen in people, and explains why we do not offer it as a casual product.
What the animal data show
A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 articles. Thirty-five were preclinical studies, several of them in cell cultures rather than whole animals. Those studies report faster healing of tendon, ligament and muscle injuries and protective effects in the gut in rodents. The reviewers judged the animal evidence promising, and that is where the research stands.
What the human data show
The same review found one clinical study in people: a retrospective report on 12 patients with chronic knee pain who received an intra-articular BPC-157 injection. Seven of the 12 reported relief lasting more than six months. A retrospective study has no control group, and the authors did not measure healing. There is no randomized trial of BPC-157 in humans that we could find, so claims about tendon repair or gut healing in people have no trial behind them.
The FDA status
In 2023 the FDA placed BPC-157 in Category 2 of its 503A bulk drug substances list. Category 2 is used for substances that FDA considers to carry significant safety concerns for compounding. The concerns named in secondary summaries are immunogenicity (the risk of an immune reaction) and peptide-related impurities from manufacturing.
Why the status keeps changing
Summaries published in 2026 disagree about whether BPC-157 was removed from Category 2, whether that removal put it in a permitted category, and what an advisory committee recommended in July 2026. Removal from Category 2 does not by itself make a substance eligible for compounding. Because of that, we check the current FDA list at each decision, and we do not describe the legal status in a fixed way on the strength of a summary.
Why we prescribe it only with oversight
Our physicians prescribe BPC-157 only after reviewing your history and the reason you want it, and they explain that the human evidence is limited. Products come from licensed U.S. pharmacies, and we monitor you while you take it: injection-site reactions, allergic symptoms, and any change in how you feel. If the benefit you hoped for does not appear, we stop and say so.
What this does not say
- Animal studies show what happened in those animals under those conditions. They do not show that the same effect happens in people at any dose.
- The one human report is small, uncontrolled and retrospective. It is a reason to study BPC-157, not a reason to expect a result.
- Injectable and oral forms are different products. Long-term safety in people has not been established for either.
- Legal status can change. Anything written here about FDA categories should be checked against fda.gov before a decision.
How we use this
We do not sell BPC-157 as a wellness product, and we do not promise tendon or gut results. We prescribe it to people whose history makes it a reasonable question to ask, and we are clear about how little human data exists.
If you have read about BPC-157 online and want to know whether it fits your case, bring the question to your consultation. A physician will tell you what the evidence can and cannot support.
Explore weight loss treatmentsSources
- 1.Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025;21(4):485-495. HSS Journal
- 2.BPC-157 and the FDA 503A bulks list: regulatory status (law firm analysis, 2026). Law firm summary
- 3.FDA 503A bulk drug substances list, Category 2 concerns, as summarized in 2026 (secondary summary; check fda.gov). Secondary summary